GLAXOSMITHKLINE PHARMACEUTICALS LTD.

NSE : GLAXOBSE : 500660ISIN CODE : INE159A01016Industry : Pharmaceuticals & DrugsHouse : Glaxosmithkline - MNC

BSE2061.55-28.65 (-1.37 %)

PREV CLOSE (Rs.) 2090.20

OPEN PRICE (Rs.) 2051.50

BID PRICE (QTY) 2063.75 (8)

OFFER PRICE (QTY) 2067.65 (4)

VOLUME 3839

TODAY'S LOW / HIGH (Rs.)2051.50 2123.15

52 WK LOW / HIGH (Rs.)1825.05 3087.95

NSE2064.10-29.25 (-1.4 %)

PREV CLOSE( Rs. ) 2093.35

OPEN PRICE (Rs.) 2100.05

BID PRICE (QTY) 2063.50 (7)

OFFER PRICE (QTY) 2064.10 (1)

VOLUME 55810

TODAY'S LOW / HIGH(Rs.) 2051.00 2118.00

52 WK LOW / HIGH (Rs.)1842.05 3088

More From Company Profile

Dividend Details

Dividend Date	Record Date	Dividend %	Interim / Final / Dividend

ATTENTION INVESTORS|KYC|IPO|PROPRIETARY TRADING

Prevent Unauthorised transactions in your account. Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day .......... Issued in the interest of investors.

ATTENTION INVESTORS Advisory for Investors Advisory - KYC Compliance

1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.
2. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.
3. Pay 20% upfront margin of the transaction value to trade in cash market segment.
4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.
5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month. .......... Issued in the interest of Investors

CORPORATE OFFICE

address

9/2003-4,
Vishnu Priya Limda Chowk
Main Road
Surat – 395 003.

call us @ +91-261-6673500 +91-261-2436536

fax us @ +91-261-6673537

email us @ info@rwadiwala.com

BSE, NSE, MCX SEBI Regn no.: INZ000187332 | PMS SEBI Regn no.: INP000004045 | CDSL SEBI Regn No.: IN-DP-112-2015 | CDSL DP ID: 12043100
| R Wadiwala Securities Pvt Ltd - CIN: U67120GJ2004PTC044324

Compliance Officer - Email ID: compliance@rwadiwala.com | Contact No.: 0261-6673542

The Stock Exchange, Mumbai is not in any manner answerable, responsible or liable to any person or persons for any acts of omission or commission, errors, mistakes and/or violation, actual or perceived, by us or our partners, agents, associates etc., of any of the Rules, Regulations, Bye-laws of the Stock Exchange, Mumbai, SEBI Act or any other laws in force from time to time. The Stock Exchange, Mumbai is not answerable, responsible or liable for any information on this Website or for any services rendered by us, our employees, and our servants.

Investor Greivance Redressal at support@rwadiwala.com

Designed & Developed by ●●● Accord Fintech Pvt. Ltd.

We are investment service provider for Buy stocks , Low Stocks Brokerage , Stocks Portfolio Management in Surat , NRI Investment in Stocks , Share Broking Surat , Stock Broking Surat , Advisory Services Surat and Competetive Stocks Brokerage.

GLAXOSMITHKLINE PHARMACEUTICALS LTD.

Dividend Details

Filing complaints on SCORES Easy & quick